Mark B. Faries
Expertise in
3
conditions

Dr. Mark B. Faries

Oncology | Surgical Oncology
11818 Wilshire Boulevard, Suite 200, 
Los Angeles, CA 
Accepting New Patients
Referral may be required
Before you request
Expertise in
3
conditions
11818 Wilshire Boulevard, Suite 200, 
Los Angeles, CA 

Overview

Mark Faries is an Oncologist and a Surgical Oncologist practicing medicine in Los Angeles, California.

Dr. Faries is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Skin Carcinoma, and Lymphadenectomy.

He is actively involved in clinical research, co-authoring 139 peer reviewed articles and participating in 4 clinical trials. Dr. Faries is currently accepting new patients.

Specialties

Oncology
Surgical Oncology

Licenses

Surgery in CA

Hospital Affiliations

Saint John's Health Center
Cedars-Sinai Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

11818 Wilshire Boulevard, Suite 200, Los Angeles, CA 90025

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine
Study Phase: Phase 2
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Combination product
Study Drug: Melphalan/Hepatic Device System
Study Phase: Phase 3
A Phase II Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) Plus IL-2 Followed by Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanomas
A Phase II Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) Plus IL-2 Followed by Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanomas
Enrollment Status: Terminated
Publish Date: September 22, 2021
Intervention Type: Biological
Study Phase: Phase 2
Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration
Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration
Enrollment Status: Terminated
Publish Date: February 21, 2019
View 3 Less Clinical Trials

139 Total Publications

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2026
Similar Doctors
Expertise in
22
conditions
Dr. Cristina R. Ferrone
Surgical Oncology
Expertise in
22
conditions
Dr. Cristina R. Ferrone
Surgical Oncology
Referral may be required

Susanne And Ervin Bard Pavilion

127 S San Vicente Blvd, 
Los Angeles, CA 
 (5.2 miles away)
310-423-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Cristina Ferrone is a Surgical Oncologist practicing medicine in Los Angeles, California. Dr. Ferrone is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatectomy, and Pancreaticoduodenectomy.

Expertise in
11
conditions
Dr. Armando E. Giuliano
Surgical Oncology
Expertise in
11
conditions
Dr. Armando E. Giuliano
Surgical Oncology
Referral may be required

Saul And Joyce Brandman Breast Center-A Project Of Women's Guild

310 N San Vicente Blvd Bldg 3RD Fl 3, 
West Hollywood, CA 
 (5.5 miles away)
310-423-9331
Languages Spoken:
English
See accepted insurances

Armando Giuliano is a Surgical Oncologist practicing medicine in West Hollywood, California. Dr. Giuliano is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Intraductal Papilloma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Lymphadenectomy.

Expertise in
40
conditions
Expertise in
40
conditions
Referral may be required

UCLA Health Bowyer Oncology Center

200 UCLA Medical Plz Ste 120, 
Los Angeles, CA 
 (2.0 miles away)
310-206-6745
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gary Schiller is an Oncologist practicing medicine in Los Angeles, California. Dr. Schiller is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Mark B. Faries

How do I make an appointment with Dr. Mark B. Faries?

You can book an appointment with Dr. Mark B. Faries by calling their office at 310-231-2164. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark B. Faries a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark B. Faries is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark B. Faries specialize in?

While Dr. Mark B. Faries is a Oncology, they have specific expertise in Melanoma, Lymphadenectomy, and Merkel Cell Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mark B. Faries participate in research or clinical trials?

Yes. Dr. Mark B. Faries has published 139 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Mark B. Faries's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark B. Faries accept my insurance?

Dr. Mark B. Faries accepts most major insurance plans, including Anthem BCBS and Blue Shield of California. We recommend calling the office directly at 310-231-2164 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Faries's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile